The Experience of HLA-B27 Test Using Flowcytometry.
- Author:
Bo Moon SHIN
1
Author Information
1. Department of Laboratory Medicine, Seoul Paik Hospital, Inje University, Korea.
- Publication Type:Original Article
- Keywords:
Flowcytometry;
HLA-B27;
Ankylosing spondylitis;
Spondyloarthropathy
- MeSH:
Antibodies, Monoclonal;
Arthritis;
Arthritis, Psoriatic;
Arthritis, Reactive;
Arthritis, Rheumatoid;
Calibration;
Female;
Fluorescein;
Fluorescence;
Gout;
HLA-B27 Antigen*;
HLA-B7 Antigen;
Humans;
Incidence;
Intervertebral Disc;
Low Back Pain;
Male;
Phycoerythrin;
Spondylarthropathies;
Spondylitis, Ankylosing
- From:Journal of Laboratory Medicine and Quality Assurance
2002;24(2):209-213
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: HLA-B27 is associated with an increased incidence of specific spondyloarthropathies(SpA), most notably ankylosing spondylitis(AS). I evaluated the cases referred for HLA-B27 antigen using flowcytometry (FCM) to find the clinical characteristics of the patients and the diagnostic utilities of median fluorescence intensity (MFI) in HLA-B27 program. METHODS: I evaluated 443 subjects of HLA-B27 cases using FACScan flowcytometry, consisted with software for automated calibration and analysis, calibration beads, and the anti-HLA- B27 fluorescein isothiocyanate (FITC)/anti-CD3 phycoerythrin (PE) monoclonal antibodies (all from Becton Dickinson, San Jose, CA). RESULTS: Of the total 443 cases, the positive rate in male cases was 44% (132/300) and it was higher than that of female cases (22.4%, 32/143). The gating procedure was failed in one sample of 443 (0.23%). The positive rates in each diagnostic criteria were as follows; AS 61.6%, gout 20.0%, herniated intervertebral disc 20%, lower back pain 25.6%, polyarthritis 16.0%, psoriatic arthritis 20.0%, rheumatoid arthritis 28.3%, reactive arthritis 26.9%, SpA, undifferentiated 31.8% and uveitis/iritis 23.8%. In AS group, 89 cases (95.7%) showed MFI values higher than 150. CONCLUSION: About 62% of AS group showed HLA-B27 positivity using FCM and the positive rates of other diseases group in SpA categories were around 20-30%. If we considered MFI value 150 as differential value, about 95% of HLA-B27 positive AS cases might not need further confirmatory study to differentiate HLA-B7.
